Nextage Therapeutics Ltd Asset Resilience Ratio
Nextage Therapeutics Ltd asset resilience ratio. Nextage Therapeutics Ltd (NXTG) has an Asset Resilience Ratio of 2.32% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NXTG defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Nextage Therapeutics Ltd (2017–2021)
Asset resilience ratio of Nextage Therapeutics Ltd from 2017 to 2021. This chart shows how Nextage Therapeutics Ltd's Asset Resilience Ratio has changed over time. Read NXTG total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Nextage Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NXTG total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA99.00K | 2.32% |
| Total Liquid Assets | ILA99.00K | 2.32% |
Asset Resilience Insights
- Limited Liquidity: Nextage Therapeutics Ltd maintains only 2.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Nextage Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Nextage Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Nextage Therapeutics Ltd Asset Resilience Ratio by Year (2017–2021)
Nextage Therapeutics Ltd asset resilience ratio by year from 2017 to 2021. The table below shows the annual Asset Resilience Ratio data for Nextage Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 2.32% | ILA99.00K ≈ $265.42 |
ILA4.27 Million ≈ $11.45K |
+1.46pp |
| 2020-12-31 | 0.86% | ILA35.00K ≈ $93.83 |
ILA4.07 Million ≈ $10.91K |
-1.17pp |
| 2019-12-31 | 2.03% | ILA122.00K ≈ $327.08 |
ILA6.01 Million ≈ $16.10K |
-0.20pp |
| 2018-12-31 | 2.23% | ILA122.00K ≈ $327.08 |
ILA5.48 Million ≈ $14.68K |
+1.24pp |
| 2017-12-31 | 0.98% | ILA122.00K ≈ $327.08 |
ILA12.39 Million ≈ $33.23K |
-- |
About Nextage Therapeutics Ltd
Nextage Therapeutics Ltd, a pharmaceutical company, develops cannabinoid-based products. The company was formerly known as Nextage Cannabis Innovation Ltd. and changed its name to Nextage Therapeutics Ltd in August 2020. The company was incorporated in 1982 and is based in Ness Ziona, Israel.